183 related articles for article (PubMed ID: 7913562)
21. Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody.
He YG; Ross J; Niederkorn JY
Invest Ophthalmol Vis Sci; 1991 Sep; 32(10):2723-8. PubMed ID: 1680112
[TBL] [Abstract][Full Text] [Related]
22. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.
Grohmann U; Silla S; Belladonna ML; Bianchi R; Orabona C; Puccetti P; Fioretti MC
Cell Immunol; 1997 Nov; 181(2):109-19. PubMed ID: 9398398
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of allograft rejection by anti-T-cell receptor-alpha beta monoclonal antibodies preserving resistance to bacterial infection.
Eto M; Yoshikai Y; Nishimura Y; Hiromatsu K; Maeda T; Nomoto K; Kong YY; Kubo RT; Kumazawa J; Nomoto K
Immunology; 1994 Feb; 81(2):198-204. PubMed ID: 8157269
[TBL] [Abstract][Full Text] [Related]
24. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
Blazar BR; Taylor PA; Vallera DA
J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
[TBL] [Abstract][Full Text] [Related]
25. Regulation of Ia+ reticulum cell sarcoma (RCS) growth in syngeneic SJL/J mice. I. Inhibition of tumor growth by passive administration of L3T4 monoclonal antibody before or after tumor inoculation.
Ohnishi K; Bonavida B
J Immunol; 1987 Jun; 138(12):4524-9. PubMed ID: 2953807
[TBL] [Abstract][Full Text] [Related]
26. CD25+CD4+ regulatory T cells develop in mice not only during spontaneous acceptance of liver allografts but also after acute allograft rejection.
Steger U; Kingsley CI; Karim M; Bushell AR; Wood KJ
Transplantation; 2006 Nov; 82(9):1202-9. PubMed ID: 17102772
[TBL] [Abstract][Full Text] [Related]
27. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo.
Fallarino F; Uyttenhove C; Boon T; Gajewski TF
J Immunol; 1996 Feb; 156(3):1095-100. PubMed ID: 8557984
[TBL] [Abstract][Full Text] [Related]
28. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
[TBL] [Abstract][Full Text] [Related]
29. Recovery of activated cytotoxic T cells from minor H incompatible tumor graft rejection sites.
Ksander BR; Streilein JW
J Immunol; 1989 Jul; 143(2):426-31. PubMed ID: 2500481
[TBL] [Abstract][Full Text] [Related]
30. Killer artificial antigen-presenting cells deplete alloantigen-specific T cells in a murine model of alloskin transplantation.
Shen C; He Y; Cheng K; Zhang D; Miao S; Zhang A; Meng F; Miao F; Zhang J
Immunol Lett; 2011 Aug; 138(2):144-55. PubMed ID: 21513739
[TBL] [Abstract][Full Text] [Related]
31. Analysis of cytotoxic T cell responses to intracameral allogeneic tumors.
Ksander BR; Streilein JW
Invest Ophthalmol Vis Sci; 1989 Feb; 30(2):323-9. PubMed ID: 2492486
[TBL] [Abstract][Full Text] [Related]
32. The multicellular tumor spheroid model. II. Characterization of the primary allograft response in unsensitized mice.
Lord EM; Nardella G
Transplantation; 1980 Feb; 29(2):119-24. PubMed ID: 6766584
[TBL] [Abstract][Full Text] [Related]
33. CD4+ helper T cells are required for resistance to a highly metastatic murine tumor.
Schild HJ; Kyewski B; Von Hoegen P; Schirrmacher V
Eur J Immunol; 1987 Dec; 17(12):1863-6. PubMed ID: 2961578
[TBL] [Abstract][Full Text] [Related]
34. Quantitative studies of the growth and rejection of allogeneic tumour cells in mouse cerebrospinal fluid. Elimination in the absence of H-2 differences.
Doherty PC; Zinkernagel RM
Clin Exp Immunol; 1975 Feb; 19(2):355-66. PubMed ID: 813923
[TBL] [Abstract][Full Text] [Related]
35. Infiltration and accumulation of precursor cytotoxic T-cells increase with time in progressively growing ocular tumors.
Ksander BR; Bando Y; Acevedo J; Streilein JW
Cancer Res; 1991 Jun; 51(12):3153-8. PubMed ID: 1904003
[TBL] [Abstract][Full Text] [Related]
36. Spontaneous immune rejection of intraocular tumors in mice.
Niederkorn JY; Meunier PC
Invest Ophthalmol Vis Sci; 1985 Jun; 26(6):877-84. PubMed ID: 3924853
[TBL] [Abstract][Full Text] [Related]
37. Selectively expanding subsets of T cells in mice by injection of interleukin-2/antibody complexes: implications for transplantation tolerance.
Boyman O; Krieg C; Letourneau S; Webster K; Surh CD; Sprent J
Transplant Proc; 2012 May; 44(4):1032-4. PubMed ID: 22564618
[TBL] [Abstract][Full Text] [Related]
38. [Immunomodulation by in vivo monoclonal antibodies during bone marrow grafts: parameters of biological monitoring].
Racadot E; Billot M; Jegu C; Hervé P; Peters A
Pathol Biol (Paris); 1989 Jun; 37(6):705-11. PubMed ID: 2674876
[TBL] [Abstract][Full Text] [Related]
39. Electronic cell volume analysis of growth and rejection of EL-4 ascites tumor cells.
Zucker RM; Harari J; Finley J; Kambour M
Am J Vet Res; 1978 Oct; 39(10):1710-2. PubMed ID: 717886
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo production of chemotactic inhibitors by tumor cells.
Cohen MC; Brozna JP; Ward PA
Am J Pathol; 1979 Mar; 94(3):603-14. PubMed ID: 106732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
